Patents by Inventor Vanessa Voskinarian-Berse

Vanessa Voskinarian-Berse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210032596
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: March 12, 2020
    Publication date: February 4, 2021
    Applicant: Celularity, Inc.
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20200330516
    Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: May 18, 2020
    Publication date: October 22, 2020
    Applicant: Celularity Inc.
    Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
  • Publication number: 20190330592
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: July 3, 2019
    Publication date: October 31, 2019
    Applicant: Celularity, Inc.
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20190153389
    Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.
    Type: Application
    Filed: May 5, 2017
    Publication date: May 23, 2019
    Applicant: CELULARITY, INC.
    Inventors: Steven A. FFISCHKOFF, Uri HERZBERG, Lin KANG, Brian MURPHY, Andrea NORDBERG, Vanessa VOSKINARIAN-BERSE, Keith WILSON, Xiaokui ZHANG, Han MYINT, Mohamed HUSSEIN
  • Publication number: 20180346877
    Abstract: Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: October 14, 2016
    Publication date: December 6, 2018
    Applicant: CELULARITY, INC.
    Inventors: Xiaokui ZHANG, Ivana DJURETIC, Lin KANG, Vanessa VOSKINARIAN-BERSE, Bhavani STOUT, Robert J. HARIRI, Wolfgang HOFGARTNER, James EDINGER, Eric LAW, Vladimir JANKOVIC
  • Patent number: 10041043
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: August 7, 2018
    Assignee: CELULARITY, INC.
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20180008637
    Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK ce3lls and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
    Type: Application
    Filed: December 30, 2015
    Publication date: January 11, 2018
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
  • Patent number: 9763983
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 19, 2017
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
  • Publication number: 20170240860
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: October 28, 2015
    Publication date: August 24, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
  • Publication number: 20170002322
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: September 12, 2016
    Publication date: January 5, 2017
    Applicant: Anthrogenesis Corporation
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG
  • Publication number: 20170000828
    Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
    Type: Application
    Filed: September 22, 2016
    Publication date: January 5, 2017
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20160362659
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 15, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Patent number: 9464274
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Stephen Jasko, Lin Kang, Eric Law, Ajai Pal, Bhavani Stout, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20160287635
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Application
    Filed: November 16, 2015
    Publication date: October 6, 2016
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Patent number: 9255248
    Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: February 9, 2016
    Assignee: Anthrogenesis Corporation
    Inventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20150366910
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Xiaokui ZHANG, Robert J. HARIRI, Vanessa VOSKINARIAN-BERSE, Lin KANG, Eric LAW, Stewart ABBOT
  • Patent number: 9216200
    Abstract: Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: December 22, 2015
    Assignee: Anthrogenesis Corporation
    Inventors: Robert J. Hariri, Mohammad A. Heidaran, Lin Kang, Neerav Dilip Padliya, Ajai Pal, Vanessa Voskinarian-Berse, Andrew Zeitlin, Xiaokui Zhang
  • Publication number: 20150307879
    Abstract: Anoikis resistant placental stem cells (arPSCs) with increased survival in low-attachment environments, and thus can advantageously be used, e.g., in therapies based on their ability to persist for longer durations of time in an unattached state. A method of modifying placental stem cells to make them anoikis resistant, comprising contacting the placental stem cells with an effective amount of modulatory RNA molecules, such that one or more genes associated with anoikis of the placental stem cells is inhibited. Further discloses are genes that are associated with anoikis for modulation.
    Type: Application
    Filed: December 13, 2013
    Publication date: October 29, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Stewart Abbot, Vanessa Voskinarian-Berse
  • Publication number: 20150190434
    Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.
    Type: Application
    Filed: January 16, 2015
    Publication date: July 9, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
  • Publication number: 20150072425
    Abstract: Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 12, 2015
    Applicant: ANTHROGENESIS CORPORATION
    Inventors: Robert J. HARIRI, Mohammad A. HEIDARAN, Stephen JASKO, Lin KANG, Eric LAW, Ajai PAL, Bhavani STOUT, Vanessa VOSKINARIAN-BERSE, Andrew ZEITLIN, Xiaokui ZHANG